A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age

This study is ongoing, but not recruiting participants.

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00092391

Purpose

The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.

Condition	Intervention	Phase
Measles Mumps Rubella Varicella	Biological: V205C, measles, mumps, and rubella virus vaccine live Biological: Comparator: Measles, Mumps, and Rubella Virus Vaccine Live	Phase III

MedlinePlus related topics: Chickenpox Measles Mumps Rubella

Drug Information available for: Rubella Vaccine

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Dose Comparison
Official Title:	A Study of V205C at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age

Further study details as provided by Merck:

Primary Outcome Measures:

Secondary Outcome Measures:

Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination.

Estimated Enrollment:	1770
Study Start Date:	February 1999

Detailed Description:

The duration of treatment is 24 months.

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

History or prior exposure to measles, mumps, rubella or varicella
History of anaphylactoid reactions or hypersensitivity to any component of the vaccine, including gelatin and neomycin

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	2004_073
Study First Received:	September 22, 2004
Last Updated:	June 2, 2006
ClinicalTrials.gov Identifier:	NCT00092391
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Herpes Zoster
Mouth Diseases
Paramyxoviridae Infections
Measles
Chickenpox
Healthy
Rubella

Herpesviridae Infections
Virus Diseases
DNA Virus Infections
Chicken pox
Stomatognathic Diseases
Salivary Gland Diseases
Mumps

Additional relevant MeSH terms:

Parotid Diseases
RNA Virus Infections
Rubulavirus Infections
Parotitis
Mononegavirales Infections

ClinicalTrials.gov processed this record on January 14, 2009